Intensity modulated radiation therapy for recurrent ovarian cancer refractory to chemotherapy

Chundury, Anupama; Apicelli, Anthony J.; DeWees, T.A.; Powell, Matthew A.; Mutch, David G.; Thaker, Premal H.; Robinson, Clifford G.; Grigsby, Perry W.; Schwarz, Julie K.

doi:10.1016/j.ygyno.2016.02.005

Cited by 35 publications

(29 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A number of studies have reported the possible benefit of localized involved-field RT (IFRT) for locoregionally recurrent EOC. With the advances of modern RT techniques, unnecessary irradiation of normal tissues can be avoided and has allowed for dose escalation with relatively lower rates of toxicity [15,29]. In a study of 102 EOC patients treated with definitive IFRT at doses greater than or equal to 45 Gy, Brown et al [30] demonstrated a 5-year in-field disease control rate of 71%.…”

Section: Discussionmentioning

confidence: 99%

Radiation for persistent or recurrent epithelial ovarian cancer: a need for reassessment

et al. 2017

View full text Add to dashboard Cite

PurposeThe role of radiotherapy (RT) was largely deserted after the introduction of platinum-based chemotherapy, but still survival rates are disappointingly low. This study focuses on assessing the clinical efficacy of RT in relation to chemotherapy resistance.Materials and MethodsFrom October 2002 to January 2015, 44 patients were diagnosed with epithelial ovarian cancer (EOC) and treated with palliative RT for persistent or recurrent EOC. All patients received initial treatment with optimal debulking surgery and adjuvant platinum-based chemotherapy. The biologically effective dose (BED) was calculated with α/β set at 10. Ninety-four sites were treated with RT with a median BED of 50.7 Gy (range 28.0 to 79.2 Gy). The primary end-point was the in-field local control (LC) interval, defined as the time interval from the date RT was completed to the date any progressive or newly recurring disease within the RT field was detected on radiographic imaging.ResultsThe median follow-up duration was 52.3 months (range 7.7 to 179.0 months). The 1-year and 2-year in-field LC rates were 66.0% and 55.0%, respectively. Comparisons of percent change of in-field tumor response showed similar distribution of responses among chemoresistant and chemosensitive tumors. On multivariate analysis of predictive factors for in-field LC analyzed by sites treated, BED ≥ 50 Gy (hazard ratio, 0.4; confidence interval, 0.2–0.9; p = 0.025) showed better outcomes.ConclusionRegardless of resistance to platinum-based chemotherapy, RT can be a feasible treatment modality for patients with persistent of recurrent EOC. The specific role of RT using updated approaches needs to be reassessed.

show abstract

Section: Discussionmentioning

confidence: 99%

Radiation for persistent or recurrent epithelial ovarian cancer: a need for reassessment

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Chundury et al stated that 82% of patients with chemotherapy resistant ovarian cancer who received radiotherapy with a median dose of 50.4 Gy were free of local recurrence at 2 years post-radiotherapy, and without high toxicity (acute GI toxicity rate = 6.1%). 24 Given radiotherapy contem-porary therapy allows direct therapy directed at tumor sites and is relatively safe for surrounding vital organs, the use of this method may be considered for recurrence in ovarian epithelial tumors. Radiotherapy targets on recurrent tumors will utilize the radiosensitive proper-ties of ovarian epithelial cancer so that it will simul-taneously reduce the amount of chemotherapy and possible chemotoxicity.…”

Section: Radiotherapy In Mbtmentioning

confidence: 99%

Ovarian Malignant Brenner Tumor

Alfianto

Rahniayu

Yuliati

2019

MOG

View full text Add to dashboard Cite

ABSTRAK Objectives: To report one malignant Brenner tumor (MBT) case in Dr. Soetomo Hospital, Surabaya, Indonesia, that underwent therapy from August 2016 to August 2017. Case report: A woman aged 62 years underwent total abdominal hysterectomy and bilateral salphingo-oophorectomy surgery with histopathologic results of malignant Brenner Tumor. From immunohistochemical examination the expression of p63 was positive. The patient had been treated with Paclitaxel carboplatin chemotherapy for 5-cycles, with the results of the last postchemotherapy evaluation showing no recidive mass. Conclusion: There was only one case of malignant ovarian Brenner Tumor in Dr Soetomo Hospital, Surabaya, Indonesia, in 2014-2016. The diagnosis can only be based on anatomic pathology examination. The specific tumor markers for malignant Brenner tumors have so far not been found. Keywords: Malignant Brenner Tumor; epithelial ovarian tumor; p63. Tujuan: Melaporkan satu kasus pasien dengan tumor Brenner di RSUD Dr. Soetomo, Surabaya, Indonesia, yang menjalani terapi dari bulan Agustus 2016 hingga Agustus 2017. Laporan kasus: Seorang wanita berusia 62 tahun menjalani histerektomi abdominal total dan operasi salphingo-ooforektomi bilateral dengan hasil histopatologis Tumor Brenner ganas. Dari pemeriksaan imunohistokimia, ekspresi p63 didapatkan positif. Pasien telah dirawat dengan kemoterapi Paclitaxel carboplatin selama 5 siklus, dengan hasil evaluasi post-kemoterapi terakhir tidak menunjukkan massa residif. Simpulan: Hanya terdapat satu kasus Tumor Brenner ovarium ganas di RSUD Dr Soetomo, Surabaya, Indonesia, antara 2014-2016. Diagnosis hanya dapat didasarkan pada pemeriksaan patologi anatomi. Penanda tumor spesifik untuk tumor Brenner ganas sejauh ini belum ditemukan. Kata kunci: Tumor Brenner ganas; tumor epitel ovarium; p63

show abstract

“…Suppression of autophagy in cisplatin-resistant ovarian cancer cells contributed to the therapeutic effect of cisplatin. Studies found that dihydroartemisinin, bortezomib and MTRR silencing inhibited cisplatin-resistant and potentiated the anticancer effect of cisplatin via inhibiting autophagy in ovarian cancer cells [43, 81, 82]. In line therewith, Chung et al identified that ellagic acid was able to assist the chemotherapy efficacy of doxorubicin by inhibiting autophagy in ovarian carcinoma ES-2 and PA-1 cells [91].…”

Section: Autophagy and Ovarian Carcinomamentioning

confidence: 99%

“…Furthermore, study suggested that resveratrol could induce human ovarian cancer cells (OVCAR-3 and Caov-3) apoptosis by triggering ATG5 expression and promoting LC3 cleavage, inhibiting autophagy with chloroquine reduced resveratrol-induced cells death [80]. Radiotherapy has been offered in the palliative setting after first-line chemotherapy failure for ovarian cancer [81]. It was estimated that treatment ovarian cancer with radiation was implicated with the activation of autophagy.…”

Section: Autophagy and Ovarian Carcinomamentioning

confidence: 99%

Autophagy as an emerging therapy target for ovarian carcinoma

et al. 2016

View full text Add to dashboard Cite

Autophagy is a conserved cellular self-digestion pathway for maintenance of homeostasis under basal and stressed conditions. Autophagy plays pivotal roles in the pathogenesis of many diseases, such as aging-related diseases, autoimmune diseases, cardiovascular diseases, and cancers. Of special note is that accumulating data suggest an intimate relationship between autophagy and ovarian carcinoma. Autophagy is well identified to act as either as a tumor-suppressor or as a tumor-promoter in ovarian carcinoma. The exact function of autophagy in ovarian carcinoma is highly dependent on the circumstances of cancer including hypoxic, nutrient-deficient, chemotherapy and so on. However, the mechanism underlying autophagy associated with ovarian carcinoma remains elusive, the precise role of autophagy in ovarian carcinoma also remains undetermined. In this review, we tried to sum up and discuss recent research achievements of autophagy in ovarian cancer. Moreover, waves of novel therapies ways for ovarian carcinoma based on the functions of autophagy were collected.

show abstract

Intensity modulated radiation therapy for recurrent ovarian cancer refractory to chemotherapy

Cited by 35 publications

References 20 publications

Radiation for persistent or recurrent epithelial ovarian cancer: a need for reassessment

Radiation for persistent or recurrent epithelial ovarian cancer: a need for reassessment

Ovarian Malignant Brenner Tumor

Autophagy as an emerging therapy target for ovarian carcinoma

Contact Info

Product

Resources

About